Related Experiment Video
Updated: May 26, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Improving the outcomes: developing cancer therapeutics
1Charite - Universitaetsmedizin Berlin, Campus Virchow-Klinikum, Institut fuer Medizinische Immunologie, Augustenburger Platz 1, 13353 Berlin, Germany. nalan.utku@charite.de
Abstract:
Oncology therapeutics are less likely to reach the market than other therapeutics, at a higher cost, and only approximately one in ten cancer drugs in clinical development actually reach the market. To improve, there need to be new approaches to oncology research and development, based on understanding cancer biology and improving preclinical models and clinical trials, such as more use of biomarkers and evaluation of other targets including cancer stem cells and use of combination therapies. Biomarkers can be used to make early go/no-go decisions in drug development and can speed up drug development by selecting patients who will benefit and excluding patients likely to experience severe side effects, but they need validation before use. New approaches to preclinical and clinical trials can also speed up and improve the development of cancer therapeutics.
Insights
Developing new oncology therapeutics faces challenges, with low success rates and high costs. Improved research, preclinical models, and clinical trials, including biomarker use and combination therapies, are crucial for advancing cancer drug development.
Area of Science:
- Oncology
- Drug Development
- Cancer Biology
Background:
- Oncology therapeutics have a low market success rate compared to other drugs.
- High costs and attrition rates characterize cancer drug development.
- Current approaches necessitate innovation in research and development.
Purpose of the Study:
- To identify key areas for improving oncology research and development.
- To explore novel strategies for enhancing cancer therapeutic development.
- To address the challenges in bringing new cancer drugs to market.
Main Methods:
- Reviewing current oncology research and development paradigms.
- Evaluating the role of cancer biology in drug discovery.
- Assessing the utility of biomarkers, novel targets (e.g., cancer stem cells), and combination therapies.
- Examining improvements in preclinical models and clinical trial designs.
Main Results:
- Understanding cancer biology is fundamental for new therapeutic approaches.
- Biomarkers aid in early decision-making and patient selection but require validation.
- Targeting cancer stem cells and employing combination therapies show promise.
- Optimized preclinical models and clinical trials can accelerate development.
Conclusions:
- Innovative strategies in oncology research and development are essential.
- Integrating biomarkers, novel targets, and combination therapies can improve success rates.
- Enhancing preclinical and clinical trial methodologies is critical for faster and more effective cancer drug development.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...